Document is current
Any future updates will be listed below
-
Authors
Rinscheid, Andreas
Gäble, Alexander
Wienand, Georgine
Dierks, Alexander
Kircher, Malte
Günther, Thomas
Patt, Marianne
Bundschuh, Ralph A.
Lapa, Constantin http://orcid.org/0000-0001-7536-2207
Pfob, Christian H. http://orcid.org/0000-0003-2989-5883
-
Funding
Funding for this research was provided by:
Universität Augsburg
- License Information
-
More Information
Article History
Received: 20 January 2024
Accepted: 15 April 2024
First Online: 26 April 2024
Declarations
:
: A patent application on modified GRPR-targeted ligands including [<sup>99m</sup>Tc]Tc-N4-BTG, with Thomas Günther as inventor, has been filed. All other authors have no potential conflict of interest.
: The authors have no relevant financial or non-financial interests to disclose.
: Written informed consent for publication was obtained from all patients.
: All procedures involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The local ethics committee (ethics committee of the Ludwig-Maximilians-Universität München, Munich, Germany) approved this retrospective analysis (permit number 22–0691). [<sup>99m</sup>Tc]Tc-N4-BTG was prepared in compliance with the German Medicines Act, AMG § 13 2b, and after notifying the responsible regulatory authority.
: Written informed consent was obtained from all individual participants included in the study.
